Results 121 to 130 of about 1,991 (194)

Association Between Baseline Hypertension and Longitudinal Functional Status in Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten. [PDF]

J Card Fail
Reza N, Mahmud N, Austin MA, Boakye E, Duqueney E, Patel P, DE Feria A, Hornsby N, Marzolf A, Owens AT.   +9 more
europepmc   +1 more source

Antihypertensive Dosing During Mavacamten Therapy for Obstructive Hypertrophic Cardiomyopathy. [PDF]

J Card Fail Intersect
Reza N, Mahmud N, Austin MA, Duqueney E, Patel P, Boakye E, Hornsby N, DE Feria A, Marzolf A, Owens AT.   +9 more
europepmc   +1 more source

Targeting the Sarcomere: Myosin Inhibitors as the Revolutionary Game Changer in Hypertrophic Cardiomyopathy. [PDF]

Rev Cardiovasc Med
Sedaghat-Hamedani F, Kayvanpour E, Meder B.   +2 more
europepmc   +1 more source

Mavacamten effectively reduces > 100 mmHg left ventricular outflow tract gradients As early as one week of treatment in obstructive hypertrophic cardiomyopathy [PDF]

Boda Krisztina, Borbás János, Kormányos Árpád, Nagy Viktória, Pintér Jenő Antal, Polestyuk Bianka Petra, Pálinkás Attila, Rácz Gergely, Schvartz Noémi, Sepp Róbert, Szili-Török Tamás, Szűcsborus Tamás, Takács Hedvig, Vidács Dániel László   +13 more
core   +1 more source

Evolving strategies in obstructive hypertrophic cardiomyopathy: myosin inhibitors as monotherapy compared with beta-blockers. [PDF]

Heart Fail Rev
Grupper A, Sverdlov AL, Cheema BS, Nasrollahizadeh A, Hosseini K.   +4 more
europepmc   +1 more source

Mavacamten in Symptomatic Hypertrophic Cardiomyopathy

JACC: Asia
Chung-Lieh Hung, Yen-Wen Liu, Yen-Wen Wu
openaire   +1 more source

Hypertrophic Obstructive Cardiomyopathy Present as Acute Myocardial Infarction in a Nonagenarian. [PDF]

JACC Case Rep
Wan X, Zhan Y, Gao Z, Sui Y, Ren J, Chen H, Chang Y, Zhang C, Wang Y.   +8 more
europepmc   +1 more source

Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Targeting Sarcomeric Hypercontractility with Demonstrated Long-Term Safety and Efficacy-A Narrative Review. [PDF]

J Clin Med
Mansour GK, Altebainawi AF, Hajjar AW, Sayed SBH, Alazem FA, Sajid MR.   +5 more
europepmc   +1 more source

Real‐world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population [PDF]

Biagioni, Giulia, Gabrielli, Domenico, Insinna, Eleonora, Marchi, Alberto, Olivotto, Iacopo, Patti, Giuseppe, Pieroni, Maurizio   +6 more
core   +1 more source

Mavacamten in the Treatment of Obstructive Hypertrophic Cardiomyopathy: from Pathophysiology To Real World Data. [PDF]

Curr Cardiol Rep
Panichella G, Garofalo M, Ragagnin M, Fanizzi AI, Zampieri M, Del Franco A, Cappelli F, Pieroni M, Olivotto I.   +8 more
europepmc   +1 more source